Back to search results

Study of Solrikitug for COPD (ZION)

This study, called ZION, is testing an investigational medicine called Solrikitug for people with Chronic Obstructive Pulmonary Disease (COPD). Solrikitug is a monoclonal antibody, a type of protein that can help the body fight disease. We are looking at two different doses of Solrikitug, given as an injection under the skin, compared to a placebo (an inactive injection). The main goal is to see how Solrikitug affects the number of eosinophils (a type of white blood cell) in your blood over 12 weeks. You may be able to join if you are between 40 and 75 years old, have a confirmed diagnosis of COPD, and have elevated blood eosinophils at screening. The study is currently status unclear and plans to enroll about 171 participants.

Study design
This is a randomized, double-blind, placebo-controlled study, meaning participants are randomly assigned to receive Solrikitug or placebo, and neither you nor your study doctor will know which you are receiving. Approximately 171 participants will be enrolled.
What's involved
You would receive Solrikitug or placebo as an injection under the skin at the study site over a 12-week treatment period.
Compensation
Not stated in the trial record.
Follow-up
After the 12-week treatment, there is a post-treatment follow-up period of 16 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06496620

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

Active, Not Recruiting
PHASE2Ages 40–75InterventionalTreatment
Uniquity One (UNI)
~182 participants
Updated 2026-08-11 on ClinicalTrials.gov
What's tested:Biological: Solrikitug low doseBiological: Solrikitug high dosePlacebo

At a glance

Recruiting sites
0 of 110 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in blood eosinophil counts
Measured over Through week 12

Conditions

COPD

Explore related trials

Chronic Obstructive Pulmonary DiseaseEosinophilia

Where it's being run

110 sites across 36 states
Florida19
Texas11
South Carolina9
North Carolina7
California6
New Zealand5
Arizona4
Georgia4

Study leadership

  • Andrew W Lee, MD · STUDY_DIRECTOR · Vice President, Clinical Research

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

At least 40 years of age and no older than 75 years.
Documented diagnosis of COPD for at least 12 months prior to Screening, defined by the GOLD Guidelines (2023), and elevated blood eosinophils at screening.
At Screening FEV1/FVC ratio must be \<0.70, and Post-bronchodilator FEV1 must be ≥40% to \<80% predicted normal value calculated using Global Lung Function Initiative (GLI) reference equations (Cooper et al 2017).
Symptomatic (COPD Assessment Test \[CAT\] Score ≥10) at Screening Visit 1.
Participants must be on 2 or more inhaled maintenance medications for management of their COPD, for at least 3 months prior to screening.

Exclusion

Female participant who is pregnant or breastfeeding.
Participant has a known hypersensitivity to any component of the formulation of solrikitug, including any of the excipients, or a history of anaphylactic reaction to any therapeutic monoclonal antibody.
Participant has history or evidence of any clinically significant cardiovascular, hematologic, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy, or any other condition that in the opinion of the Investigator or Medical Monitor might obfuscate the study data.
Any other pulmonary disease than COPD that in the opinion of the Investigator, the severity of the disorder would impact the conduct of the study.
Undergone major lung surgery, within 1 year of Screening Visit 1.
Participant has a lower respiratory tract infection that required antibiotics within 6 weeks prior to Screening.

What this trial measures

  • Change from baseline in blood eosinophil countsThrough week 12

    To assess the effect of multiple doses of solrikitug on blood eosinophil counts compared with placebo